Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Department of Gastroenterology and Hepatology, University of Groningen, and University Medical Center Groningen, Groningen, the Netherlands.
Diabetes Care. 2022 Sep 1;45(9):2084-2094. doi: 10.2337/dc21-2225.
People with type 1 diabetes are at risk for developing micro- and macrovascular complications. Little is known about the gut microbiome in long-standing type 1 diabetes. We explored differences in the gut microbiome of participants with type 1 diabetes compared with healthy control subjects and associated the gut microbiome with diabetes-related complications.
Microbiome data of 238 participants with type 1 diabetes with an average disease duration of 28 ± 15 years were compared with 2,937 age-, sex-, and BMI-matched individuals. Clinical characteristics and fecal samples were collected, and metagenomic shotgun sequencing was performed. Microbial taxonomy was associated with type 1 diabetes-related characteristics and vascular complications.
No significant difference in the α-diversity of the gut microbiome was found between participants with type 1 diabetes and healthy control subjects. However, 43 bacterial taxa were significantly depleted in type 1 diabetes, while 37 bacterial taxa were significantly enriched. HbA1c and disease duration explained a significant part of the variation in the gut microbiome (R2 > 0.008, false discovery rate [FDR] <0.05), and HbA1c was significantly associated with the abundance of several microbial species. Additionally, both micro- and macrovascular complications explained a significant part of the variation in the gut microbiome (R2 > 0.0075, FDR < 0.05). Nephropathy was strongly associated with several microbial species. Macrovascular complications displayed similar associations with nephropathy.
Our data show that the gut microbiome is altered in people with (long-standing) type 1 diabetes and is associated with glycemic control and diabetes-related complications. As a result of the cross-sectional design, the causality of these relationships remains to be determined.
1 型糖尿病患者存在发生微血管和大血管并发症的风险。人们对长期 1 型糖尿病患者的肠道微生物组知之甚少。我们探讨了 1 型糖尿病患者与健康对照者肠道微生物组的差异,并将肠道微生物组与糖尿病相关并发症相关联。
将平均病程为 28±15 年的 238 例 1 型糖尿病患者的微生物组数据与 2937 名年龄、性别和 BMI 匹配的个体进行比较。收集临床特征和粪便样本,并进行宏基因组鸟枪法测序。对微生物分类与 1 型糖尿病相关特征和血管并发症进行关联分析。
1 型糖尿病患者与健康对照者的肠道微生物组 α 多样性无显著差异。然而,1 型糖尿病患者中有 43 种细菌分类群明显减少,而 37 种细菌分类群明显增加。HbA1c 和病程解释了肠道微生物组变异的很大一部分(R2>0.008,错误发现率[FDR] <0.05),HbA1c 与几种微生物物种的丰度显著相关。此外,微血管和大血管并发症都解释了肠道微生物组变异的很大一部分(R2>0.0075,FDR <0.05)。肾病与几种微生物物种密切相关。大血管并发症与肾病也存在相似的关联。
我们的数据表明,肠道微生物组在(长期)1 型糖尿病患者中发生改变,并与血糖控制和糖尿病相关并发症相关。由于采用了横断面设计,这些关系的因果关系仍有待确定。